Oxa-Med

58,00 €

Achieve a lean, defined physique with Oxa-Med, a premium and versatile androgen designed for strength and fat management.

SKU: oxa-med Categories: ,

Oxa-Med

Active Formulation

Oxa-Med is a high-quality anabolic compound often utilized for its lean-building and strength-enhancing properties.

Pharmacodynamics

Oxa-Med is widely recognized for its ability to promote significant muscle growth while maintaining a lean appearance. It works by enhancing protein synthesis and optimizing the body’s nitrogen balance. Unlike many other androgens, it is often favored for its ability to support fat loss and calorie management, making it an excellent choice for “cutting” phases or for those looking to build muscle with minimal water retention.

Classification

Anabolic and Androgenic Steroids (AAS).

Contraindications

This medication should not be used by individuals with:

  • Severe liver or kidney complications.
  • Prostate or breast cancer.
  • History of cardiovascular issues.
  • Pregnancy or nursing.

Note: Users should monitor liver enzymes and lipid profiles during the cycle.

Safety & Precautions

While Oxa-Med is known for its lean-building properties, it still possesses anabolic effects. Users should be aware of potential side effects like acne, hair loss, and fluctuations in mood. Regular consultation with a healthcare professional is recommended to ensure safe usage.

Potential side effects may include: Acne, hair loss, mood changes, and water retention.

Recommended Dosage

Dosage should be tailored to the individual’s goals and previous experience:

  • Adult Males: Typically 200 – 400 mg per week.
  • Females: Typically 50 – 100 mg per week.

Dosage should be adjusted gradually to determine individual tolerance.

Storage Conditions

Store in a cool, dry environment. Protect from direct sunlight.

* Always seek professional medical advice before starting any new pharmacological protocol.

Reviews

There are no reviews yet.

Be the first to review “Oxa-Med”

Your email address will not be published. Required fields are marked *